Kalaris Therapeutics, Inc. (KLRS)

Market Cap	160.84M
Revenue (ttm)	n/a
Net Income (ttm)	-69.17M
Shares Out	18.70M
EPS (ttm)	-10.44
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	18,580
Open	9.22
Previous Close	9.01
Day's Range	8.50 - 9.22
52-Week Range	7.96 - 24.15
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	May 15, 2025

About KLRS

Kalaris Therapeutics, Inc., a clinical-stage ophthalmology biotech company, engages in developing therapies for the treatment of neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024. The company was incorporated in 2019 and is based in Palo Alto, California.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2019
• Country: United States
• Stock Exchange: NASDAQ
• Ticker Symbol: KLRS
• Website: https://kalaristx.com